These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Type-2 hepatorenal syndrome and refractory ascites: role of transjugular intrahepatic portosystemic stent-shunt in eighteen patients with advanced cirrhosis awaiting orthotopic liver transplantation. Testino G; Ferro C; Sumberaz A; Messa P; Morelli N; Guadagni B; Ardizzone G; Valente U Hepatogastroenterology; 2003; 50(54):1753-5. PubMed ID: 14696397 [TBL] [Abstract][Full Text] [Related]
3. TIPS for the treatment of refractory ascites, hepatorenal syndrome and hepatic hydrothorax: a critical update. Rössle M; Gerbes AL Gut; 2010 Jul; 59(7):988-1000. PubMed ID: 20581246 [TBL] [Abstract][Full Text] [Related]
4. Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis. Ginès P; Uriz J; Calahorra B; Garcia-Tsao G; Kamath PS; Del Arbol LR; Planas R; Bosch J; Arroyo V; Rodés J Gastroenterology; 2002 Dec; 123(6):1839-47. PubMed ID: 12454841 [TBL] [Abstract][Full Text] [Related]
5. Management of ascites. Yu AS; Hu KQ Clin Liver Dis; 2001 May; 5(2):541-68, viii. PubMed ID: 11385975 [TBL] [Abstract][Full Text] [Related]
6. Refractory Ascites in Liver Cirrhosis. Adebayo D; Neong SF; Wong F Am J Gastroenterol; 2019 Jan; 114(1):40-47. PubMed ID: 29973706 [TBL] [Abstract][Full Text] [Related]
7. Management of ascites in the patient with portal hypertension with emphasis on spontaneous bacterial peritonitis. Navasa M; Rodés J Semin Gastrointest Dis; 1997 Oct; 8(4):200-9. PubMed ID: 9360284 [TBL] [Abstract][Full Text] [Related]
8. Refractory Ascites: Pathogenesis, Clinical Impact, and Management. Siqueira F; Kelly T; Saab S Gastroenterol Hepatol (N Y); 2009 Sep; 5(9):647-656. PubMed ID: 37967427 [TBL] [Abstract][Full Text] [Related]
9. Albumin May Prevent the Morbidity of Paracentesis-Induced Circulatory Dysfunction in Cirrhosis and Refractory Ascites: A Pilot Study. Tan HK; James PD; Wong F Dig Dis Sci; 2016 Oct; 61(10):3084-3092. PubMed ID: 27048451 [TBL] [Abstract][Full Text] [Related]
11. An experience with covered transjugular intrahepatic portosystemic shunt for refractory ascites from western India. Amarapurkar DN; Punamiya S; Patel ND Ann Hepatol; 2006; 5(2):103-8. PubMed ID: 16807516 [TBL] [Abstract][Full Text] [Related]
12. Ascites in cirrhosis: a review of management and complications. Kuiper JJ; van Buuren HR; de Man RA Neth J Med; 2007 Sep; 65(8):283-8. PubMed ID: 17890787 [TBL] [Abstract][Full Text] [Related]
13. The transjugular intrahepatic portosystemic shunt for the management of cirrhotic refractory ascites. Garcia-Tsao G Nat Clin Pract Gastroenterol Hepatol; 2006 Jul; 3(7):380-9. PubMed ID: 16819501 [TBL] [Abstract][Full Text] [Related]
14. Management of refractory ascites and hepatorenal syndrome. Chutaputti A J Gastroenterol Hepatol; 2002 Apr; 17(4):456-61. PubMed ID: 11982727 [TBL] [Abstract][Full Text] [Related]
15. Transjugular intrahepatic portosystemic shunt (TIPS) placement: A comparison of outcomes between patients with hepatic hydrothorax and patients with refractory ascites. Young S; Bermudez J; Zhang L; Rostambeigi N; Golzarian J Diagn Interv Imaging; 2019 May; 100(5):303-308. PubMed ID: 30522911 [TBL] [Abstract][Full Text] [Related]
16. An update on the pathogenesis and clinical management of cirrhosis with refractory ascites. Neong SF; Adebayo D; Wong F Expert Rev Gastroenterol Hepatol; 2019 Apr; 13(4):293-305. PubMed ID: 30791777 [TBL] [Abstract][Full Text] [Related]